健康成人采用调整后新冠疫苗接种程序的SARS-CoV-2体液免疫应答:IMCOVAS随机临床试验
该部分单盲、多中心疫苗试验将566名未感染COVID-19的健康成人随机分配至由BNT162b2、mRNA-1273和ChAdOx1-S组合而成的8个治疗组之一,评估较低剂量、皮内接种及异源程序等调整程序的体液免疫原性及加强接种后免疫。结果显示,将接种间隔从28天延长至84天、使用异源BNT162b2+mRNA-1273程序及低剂量mRNA-1273均诱导非劣效免疫应答;皮内接种未能证明非劣效。所有调整程序首剂加强后抗RBD IgG滴度均非劣效于其参考程序。
要点
- 延长接种间隔至84天或采用异源BNT162b2+mRNA-1273程序,免疫应答非劣效于参考程序。
- 低剂量mRNA-1273足以诱导非劣效免疫。
- 皮内接种未能证明非劣效;加强后免疫不取决于加强疫苗剂量或品牌。
核心结论
- 研究提示参考疫苗程序可被调整而不损害充分免疫应答的发展。
- 加强接种后的免疫不取决于加强疫苗的剂量或品牌,这对未来加强运动具有相关性。
研究设计与样本
- 部分单盲、多中心疫苗试验,将566名未感染COVID-19的健康成人随机分配至由BNT162b2、mRNA-1273和ChAdOx1-S组合而成的8个治疗组之一。
- 评估抗受体结合域免疫球蛋白G(RBD IgG)滴度、中和抗体滴度及抗RBD IgG亲和力,随访至研究开始后1年。
- 试验注册于欧盟临床试验注册库(编号2021-001993-52)和clinicaltrials.gov(NCT06189040)。
主要发现
- 将接种间隔从28天延长至84天及使用异源BNT162b2+mRNA-1273程序,与参考程序相比诱导非劣效免疫应答。
- 低剂量mRNA-1273足以诱导非劣效免疫。
- 皮内接种未能证明非劣效。
- 所有调整程序首剂加强接种后测得的抗RBD IgG滴度均非劣效于其参考程序。
临床怎么用
- 作者认为参考疫苗程序可被调整而不损害充分免疫应答的发展。
- 作者指出加强接种后的免疫不取决于加强疫苗的剂量或品牌,这对未来加强运动具有相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To overcome supply issues of COVID-19 vaccines, this partially single blind, multi-centric, vaccine trial aimed to evaluate humoral immunogenicity using lower vaccine doses, intradermal vaccination, and heterologous vaccine schedules. Also, the immunity after a booster vaccination was assessed. METHODOLOGY: 566 COVID-19-naïve healthy adults were randomized to 1 of 8 treatment arms consisting of combinations of BNT162b2, mRNA-1273, and ChAdOx1-S. Anti-Receptor-Binding Domain immunoglobulin G (RBD IgG) titers, neutralizing antibody titres, and avidity of the anti-RBD IgGs was assessed up to 1 year after study start. RESULTS: Prolonging the interval between vaccinations from 28 to 84 days and the use of a heterologous BNT162b2 + mRNA-1273 vaccination schedule led to a non-inferior immune response, compared to the reference schedule. A low dose of mRNA-1273 was sufficient to induce non-inferior immunity. Non-inferiority could not be demonstrated for intradermal vaccination. For all adapted vaccination schedules, anti-RBD IgG titres measured after a first booster vaccination were non-inferior to their reference schedule. CONCLUSION: This study suggests that reference vaccine schedules can be adapted without jeopardizing the development of an adequate immune response. Immunity after a booster vaccination did not depend on the dose or brand of the booster vaccine, which is relevant for future booster campaigns. The trial is registered in the European Union Clinical Trials Register (number 2021-001993-52) and on clinicaltrials.gov (NCT06189040).
引用
- Steenackers K, Hanning N, Bruckers L, et al. Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial. Vaccine. 2024. PMID: 39019657. doi:10.1016/j.vaccine.2024.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。